Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Flotetuzumab (MGD006) is a humanized bispecific antibody that targets both CD123 and CD23, which may lead to anti-leukemic activity (Blood 2017 130(Suppl 1):637).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Flotetuzumab||MGD006|S80880||Flotetuzumab (MGD006) is a humanized bispecific antibody that targets both CD123 and CD23, which may lead to anti-leukemic activity (Blood 2017 130(Suppl 1):637, PMID: 32493790, PMID: 32929488).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||Flotetuzumab||Phase I||Actionable||In a Phase I/II trial, Flotetuzumab (MGD006) treatment demonstrated acceptable safety and tolerability, and resulted in an overall response rate of 30% (9/30; 5 complete response (CR), 3 CRh, 1 CRi) and a median overall survival of 11.2 months in heavily pretreated acute myeloid leukemia patients with either primary induction failure (n=24) or early relapse (n=6), and in patients who achieved CR/CRh, resulted in a median duration of response of 6.9 months (PMID: 32929488; NCT02152956).||32929488|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02152956||Phase Ib/II||Flotetuzumab||Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS||Recruiting||USA||5|
|NCT03739606||Phase II||Flotetuzumab||Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer||Withdrawn||0|
|NCT04582864||Phase II||Flotetuzumab||Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)||Not yet recruiting||USA||0|